On December 4, 2024, Torrent Pharmaceuticals Limited announced that it has entered into an agreement to acquire the brands Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin), and Xilingio (empagliflozin + linagliptin) from Boehringer Ingelheim International GmbH (BI). The company further added that the acquisition is expected to be completed by March 2025. In addition, Torrent has been marketing these brands since 2022 under an existing co-marketing agreement with Boehringer Ingelheim India.
Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, is indicated for glycemic control in adults with type 2 diabetes. The SGLT-2 inhibitors market is valued at ₹3,235 crore and is growing faster than the overall diabetes market at a 25% CAGR. India, with the second-largest diabetes patient base globally (74.2 million adults as of 2021), is projected to see this number rise to nearly 125 million by 2045. The Indian diabetes medications market is valued at ₹19,912 crore, growing at a 7.7% CAGR as per AWACS MAT October 2024 data.
Commenting on the agreement, Aman Mehta, Director, Torrent said: “As we continue to strengthen our diabetes care portfolio, we will ensure continued access to the treatment for patients whilst building on our presence in the Oral Anti Diabetic market”
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Companies involved in the research, development, manufacturing and marketing of generic pharmaceutical formulations. On December 5, 2024, Torrent Pharma shares opened at ₹3,450.00 and touched the day high of ₹3450.00 at 09:45 AM.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
